Security: Series E Preferred
Location: Ann Arbor, MI

CEO: Robert Zerbe
CFO: Gary Onn

New Investors: Venrock, T. Rowe Price, Catella Healthcare, Hercules Technology Growth Capital
Existing Investors: Frazier Healthcare Ventures, TL Ventures, MPM Capital, InterWest Partners, Thomas Weisel Healthcare Ventures, Stockwell Capital, H&B Capital, BioMedical Ventures, Bio Fund Ventures, Twilight Venture Partners

Board of Directors: Christopher Ehrlich, Richard Fox, Patrick Heron, Anders Hove, Christopher Moller, Nicholas Simon, August Watanabe, Anders Wiklund, Robert Zerbe

- QuatRx is a late-stage private company with a portfolio of drug candidates that each address an important medical need and represents a potential billion-dollar commercial opportunity.

- QuatRx is led by an experienced management team that previously worked at Parke-Davis, where they were responsible for the clinical development and commercialization of the largest selling drug in history, $12 billion Lipitor.

- QuatRx selected Aquilo Partners to help it with a last private round after withdrawing its registration statement for an IPO due to market conditions.

- Aquilo Partners managed a global distribution effort and built a strong syndicate of U.S. and European investors.

- Aquilo Partners worked with the company specifically to identify crossover investors that could support the company going forward.


- "The strong interest we've received from these leading investors and the continued support from our existing investors reflect the excitement we share as we approach upcoming milestones for our clinical development programs." - Robert Zerbe, CEO & Founder, QuatRx Pharmaceuticals.